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Abstract. Aims: X-linked Alport syn-
drome (AS) is a monogenic inherited disor-
der of type IV collagen, a structural protein 
in the kidney and cochlea. Males typically 
exhibit a severe phenotype with end-stage 
renal disease (ESRD) and/or deafness by 
early adulthood. Because of the presence of 
two X chromosomes, females often have a 
less severe phenotype and hence the diag-
nosis of AS is often not considered. Herein, 
we present a case of an adolescent girl with 
proteinuria and hematuria in the setting of 
a strong family history of AL. Case report: 
The mother and maternal aunt of the pro-
band had both presented with dipstick posi-
tive hematuria and proteinuria at age 8 years. 
These girls were not evaluated by nephrol-
ogy until mid-adolescence when they had 
worsening creatinine levels. Kidney biopsy 
in the younger sister demonstrated segmental 
glomerulosclerosis with segmental thinning 
and lamination of the glomerular basement 
membrane, consistent with AS. Kidney bi-
opsy in the older sister was performed just 
prior to the need for renal replacement ther-
apy and showed only global glomeruloscle-
rosis. Both sisters were transplanted by the 
age of 20 years. Their mother subsequently 
developed ESRD at age 53 years. With the 
advent of genetic testing, the proband and 
her family were brought in for evaluation. 
It had been assumed this family of AS had 
autosomal dominant transmission, however, 
genetic testing of the proband was positive 
for a splice site mutation of COL4A5 located 
on the X-chromosome. Sequencing of genes 
COL4A3, COL4A4, and COL4A6 were nega-
tive for mutation. Conclusions: The current 
case report demonstrates the importance of 
considering skewed X-inactivation in fe-
males who exhibit signs or symptoms of X-
linked disorders.
Introduction
Alport Syndrome (AS) is a Mendelian 
genetic disorder characterized by hematu-
ria, progressive renal dysfunction and hear-
ing loss. The prevalence of AS has been es-
timated at 1 : 5,000 from a cohort in Utah 
[1], but was much less common (1 : 53,000) 
in a Northern European cohort [2]. X-linked 
Alport Syndrome (XLAS) was previously 
considered the mode of inheritance for the 
vast majority of AS [3], however, next gen-
eration sequencing has recently revealed that 
XLAS accounts for between 37 and 65% of 
AS, while autosomal dominant transmission 
accounts for ~ 26 – 31% [4, 5]. AS is a dis-
ease caused by mutation in one or more of the 
α-chains forming type IV collagen which is 
important to the structural integrity of base-
ment membranes in the glomerulus, cochlea, 
and eye [6].
Type IV collagen is comprised of a set of 
six distinct α-chains, α1(IV) to α6(IV), which 
self-assemble to form three distinct heterotri-
meric helices: α1α1α2, α3α4α5, and α5α5α6. 
XLAS is caused by defects in α5(IV) chain, 
resulting in either absent or aberrant a3α4α5 
and α5α5α6 helices. In hemizygous males, 
progressive renal dysfunction and end-stage 
renal disease (ESRD) occurs in 90% of in-
dividuals by age 40 [7]. Hearing loss also 
occurs in 90% of males and is characterized 
by symmetrical deficits in detection of high 
frequency sounds, usually manifest by late 
childhood [3]. Ocular abnormalities are com-
mon in men, in whom ~ 15% exhibit anterior 
lenticonus which is associated with reduced 
visual acuity and cataracts [8]. Female car-
riers of XLAS typically have a less severe 
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phenotype than males [7]. It is commonly 
known that the vast majority will still have 
microscopic hematuria and proteinuria, but 
the risk for worsening renal function and 
hearing loss is vastly underappreciated. The 
following case report underscores the need 
for recognition of a possible X-linked carrier 
state in females with prompt subspecialty re-
ferral to evaluate and delay the progression 
of disease.
Case report
A 13-year-old girl was brought in for 
evaluation because of the finding of hema-
turia and proteinuria. The child’s creatinine 
was 0.7 mg/dL, and urine protein : creati-
nine ratio was 0.8 g/g. Both her mother and 
maternal aunt had been clinically diagnosed 
with AS during young adulthood and hence 
were presumed to be autosomal dominant.
The proband’s mother was first evaluated 
by nephrology at the age of 16 years. She 
was referred for evaluation of hematuria and 
proteinuria on urinary dipstick dating back to 
the age of 8 years old. Her blood pressure 
was 120/88 mmHg, and she had trace biped-
al edema. Her creatinine was 1.4 mg/dL and 
24-hour urine protein, 10.5 g. She underwent 
kidney biopsy for which light microscopy 
revealed 2/17 globally sclerosed glomeruli, 
3/17 with segmental sclerosis and variable 
moderate to moderately severe interstitial 
fibrosis and tubular atrophy. Immunofluores-
cence microscopy was trace-positive for IgM 
only. Electron microscopy demonstrated 
segmental thinning and variable wrinkling 
of the glomerular basement membrane with 
variable segmental lamination. There were 
no electron-dense deposits or inclusions. 
There was variable effacement of epithelial 
foot processes with focal microvillous trans-
formation (Figure 1). Immunofluorescent 
staining for collagen IV was not available at 
the time; however, all findings were consis-
tent with AS. She was begun on an angioten-
sin converting enzyme inhibitor, but suffered 
a rapid deterioration in her renal function and 
was on hemodialysis after 12 months.
The maternal aunt had also had a history 
of hematuria and proteinuria since the age of 
8 years. At age 10, she was diagnosed with 
type 1 diabetes after presenting with diabetic 
ketoacidosis. It is unknown whether she was 
ever on an ACEI, and she had a rapid pro-
gression of renal failure with her creatinine 
rising from 0.9 mg/dL at age 16 years to 4.4 
mg/dL 2 years later. Her 24-hour urine pro-
tein was 14 g. She did not have retinopathy. 
She underwent kidney biopsy at 18 years, 
with the finding of advanced global glomer-
ulosclerosis; hence an exact etiology could 
not be ascertained. Given that the biopsy and 
renal disease progression were atypical for 
diabetes, her hematuria and proteinuria pre-
dated her diabetes, and her sister had proven 
AS, the primary etiology of her kidney fail-
ure was suspected to be autosomal dominant 
AS. She was started on dialysis less than 2 
months later and was transplanted at the age 
of 21 years.
The proband was hence brought in for 
genetic testing in an effort to avoid kidney 
biopsy. Although it had been assumed that 
the proband’s mother and maternal aunt 
had autosomal dominant AS, COL4A5 was 
prioritized for testing given the absence of 
known disease in the maternal grandparents. 
COL4A5 genetic analysis was performed us-
ing DNA mutation scanning by high reso-
lution melting analysis (HRMA) of the 51 
coding exons and flanking intronic regions 
of the COL4A5 gene followed by sequenc-
Figure 1. Electron micrograph from kidney biopsy 
of the proband’s mother demonstrating character-
istic findings of Alport’s carrier state. The glomeru-
lar basement membranes have variable segmental 
lamination, creating a “basket weave” appearance 
and there is segmental foot process effacement 
with microvillus transformation.
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ing of genomic regions positive by HRMA. 
A heterozygous splicing mutation in intron 
8 was identified: COL4A5 IVS8-1G>A. This 
novel mutation disrupts a conserved splice 
acceptor site and is therefore predicted to be 
deleterious. Although this mutation has not 
been previously described, splice site muta-
tions typically result in defects in RNA splic-
ing and result in an aberrant protein. Splicing 
mutations resulting in exon skipping have 
previously been described in association 
with AS [9]. Therefore these results are con-
sistent with a diagnosis of X-linked AS.
Subsequent to genetic testing, the maternal 
grandmother was admitted to the hospital for 
pneumonia at age 53 years and was found to 
be in florid kidney failure. She had not sought 
prior medical care and did not know that she 
had kidney disease. At this point, the mother, 
maternal aunt, and maternal grandmother pre-
sented for next generation genetic testing of 
all three AS causing genes: COL4A3, COLA4 
COL4A5 and COL4A6. All three women had 
the same COL4A5 IVS8-1G>A mutation as 
the proband. No other mutations were found. 
The parents of the maternal grandmother 
have both lived into their 70s and have had 
no known kidney disease. It is assumed that 
this was a spontaneous mutation in the ma-
ternal grandmother. The pedigree for this 
family is depicted in Figure 2. None of the 
women in the current report have opted to 
undergo hearing or ocular evaluation but 
have reported no clinically relevant hearing 
or visual defects.
Discussion
Female “carriers” are frequently consid-
ered to be “protected” from X-linked dis-
orders since they harbor a wild-type copy 
on the other X chromosome. Despite the 
wealth of our molecular understanding of 
X-inactivation and clinical documentation, 
X-linked disorders are often not considered 
in the differential diagnosis for females pre-
senting with signs or symptoms of X-linked 
disease. Female carriers of XLAS exhibit 
extensive phenotypic heterogeneity with re-
spect to age of onset and rapidity of disease 
progression. Studies have demonstrated that 
12% of females develop ESRD by age 40, 
and 30 – 40% of female carriers will devel-
op ESRD by age 60 [10]. Hearing loss also 
manifests in roughly 10% of XLAS female 
carriers by middle-age [10].
There is a significant degree of pheno-
typic heterogeneity amongst both males and 
females with XLAS. Heterogeneity in the 
hemizygous male is largely due to genotype-
phenotype correlation, wherein more severe 
mutations in the protein result in more se-
vere clinical manifestations [7]. Generally, 
nonsense mutations or large deletions typi-
cally result in earlier onset of disease with 
more rapid deterioration in renal function 
and hearing loss, versus missense or splice 
site mutations which often result in milder 
phenotypes [7]. In contrast, phenotypic het-
erogeneity in heterozygous females is less 
well explained by genotype-phenotype cor-
relation [9]. Recently, evidence in a murine 
model has implicated skewing of X-inacti-
vation as the likely mechanism underlying 
the variability of disease severity in female 
XLAS carries [11].
The distribution of sex chromosomes 
results in an inequality of gene copy num-
ber between males (XY) and females (XX). 
To circumvent this imbalance, females ran-
domly inactivate one of the two X chro-
mosomes in any cell line [12]. Since this 
is usually a stochastic event, females have 
Figure 2. Pedigree for this case report of Alport 
syndrome; UPC = urine:protein creatinine ratio; 
SCr = serum creatinine. 
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a mosaic population of cells that express 
either the maternally or the paternally de-
rived X chromosome, typically 50 : 50 [12]. 
Given the random nature of X-inactivation, 
a single organ may have a pattern that de-
viates or skews from the expected ratio, po-
tentially leading to an imbalance as great as 
80 : 20 [13]. Thus, unfavorable skewing of 
X-inactivation, such that the wild-type allele 
becomes silenced, may underlie the pheno-
typic variability seen in female carriers of 
X-linked disorders. Non-random skewing 
of X-inactivation has also been documented 
in which the diseased allele either confers a 
selective advantage or regulates the inactiva-
tion process [14].
Close monitoring and timely therapy in 
patients with X-linked AS, as well as carri-
ers, can delay the progression of disease [15, 
16]. Angiotensin-converting enzyme (ACE) 
inhibition has been shown to delay renal 
failure and prolong life expectancy in males 
with XLAS and in individuals with autoso-
mal recessive AS [14]. AS carriers treated 
with renin-angiotensin-aldosterone system 
(RAAS) blockade have been noted to have 
a significantly later onset of ESRD than in 
those without RAAS blockade treatment 
[15]. Carriers of AS are often excluded from 
clinical trials, however, and clinical practice 
guidelines often focus on treating male pa-
tients [17].
This case report reflects the importance 
of recognizing the potential for clinical man-
ifestations of XLAS in females throughout 
the lifespan. There is significant opportu-
nity to impact the disease course of AS in 
the carrier state with aggressive blood pres-
sure control and RAAS blockade and hence 
physicians should be cognizant of this when 
caring for patients. Natural history studies of 
clinical outcomes and the pattern of X-inac-
tivation may help to predict disease progres-
sion in female carrier patients.
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